Rony Abou-Jawde, MD
Medical Oncology · St Joseph, MONPI 1548226541
Payments from drug & device makers
Across 237 payments — averaging $288.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$40K
- Bristol Myers Squibb$19K
- E.r. Squibb & Sons, L.L.C.$3K
- Puma Biotechnology, Inc.$2K
- Merck$830
- Novartis$336
- plus $2K from 26 others
What the payments were for
- Food & beverage$2,92888%
- Education$40212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 19 | $40,476 |
| Bristol Myers Squibb | 18 | $19,284 |
| E.r. Squibb & Sons, L.L.C. | 35 | $3,037 |
| Puma Biotechnology, Inc. | 2 | $2,113 |
| Merck | 23 | $830 |
| Novartis | 24 | $336 |
| Pfizer | 23 | $275 |
| Astellas Pharma US Inc | 11 | $247 |
| Genentech USA, Inc. | 12 | $243 |
| AbbVie | 9 | $220 |
| AstraZeneca | 9 | $190 |
| Daiichi Sankyo Inc. | 3 | $144 |
| Johnson & Johnson(2 entities) | 9 | $127 |
| Merit Medical Systems Inc | 1 | $115 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $111 |
| Lilly USA, LLC | 8 | $108 |
| Array Biopharma Inc | 5 | $79 |
| EMD Serono, Inc. | 3 | $54 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Sanofi | 2 | $42 |
| Amgen | 3 | $42 |
| Clovis Oncology, Inc. | 2 | $30 |
| Gilead(2 entities) | 2 | $26 |
| Tersera Therapeutics LLC | 1 | $18 |
| GSK | 1 | $17 |
| Iovance Biotherapeutics, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| Tesaro, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Verastem, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,311 in reported general payments places this provider in the 45th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 106 | $1,526,260 |
| XtandiEnzalutamide | 106 | $1,346,626 |
| RevlimidLenalidomide | 72 | $1,197,417 |
| CalquenceAcalabrutinib Maleate | 78 | $1,186,294 |
| CabometyxCabozantinib S-Malate | 36 | $952,721 |
| ImbruvicaIbrutinib | 39 | $614,556 |
| LonsurfTrifluridine/Tipiracil Hcl | 26 | $466,400 |
| InlytaAxitinib | 16 | $319,153 |
| Abiraterone Acetate | 185 | $307,050 |
| FruzaqlaFruquintinib | 11 | $270,949 |
| PomalystPomalidomide | 12 | $266,636 |
| PiqrayAlpelisib | 11 | $246,801 |
| TagrissoOsimertinib Mesylate | 13 | $216,315 |
| VenclextaVenetoclax | 22 | $144,164 |
| Imatinib Mesylate | 31 | $73,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $190 | $1,402,60991 claims |
| Astellas Pharma US IncXtandi | $247 | $1,346,626106 claims |
| Bristol Myers SquibbRevlimid | $19,284 | $1,197,41772 claims |
| Exelixis Inc.Cabometyx | $16 | $952,72136 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $111 | $614,55639 claims |
| PfizerInlyta, Eliquis | $275 | $335,17838 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $3,037 | $266,63612 claims |
| NovartisPiqray | $336 | $246,80111 claims |
| AbbVieVenclexta | $220 | $144,16422 claims |
| Johnson & JohnsonXarelto | $127 | $17,77217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in St Joseph
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Timothy PluardKansas City$14.7M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.